Catalyst Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Catalyst Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 7.4% ve 8.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 6.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 23.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

7.4%

Kazanç büyüme oranı

6.82%

EPS büyüme oranı

Biotechs kazanç büyümesi	23.9%
Gelir büyüme oranı	8.4%
Gelecekteki özkaynak getirisi	23.55%
Analist kapsamı	Good
Son güncelleme	10 Nov 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Does Catalyst Pharmaceuticals (NASDAQ:CPRX) Deserve A Spot On Your Watchlist?

Sep 26

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma

May 31

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors

May 30

Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely

Feb 21

We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

Dec 19

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Nov 13

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Nov 07

Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth

Sep 10 Diversification and expansion strategies, including new product launches and international partnerships, contribute to financial stability and potential global revenue growth.

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CPRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	666	237	253	N/A	5
12/31/2026	620	232	259	283	7
12/31/2025	578	200	210	222	7
9/30/2025	578	218	235	235	N/A
6/30/2025	558	209	275	275	N/A
3/31/2025	535	197	268	268	N/A
12/31/2024	492	164	239	240	N/A
9/30/2024	460	143	186	225	N/A
6/30/2024	434	68	79	197	N/A
3/31/2024	411	65	46	163	N/A
12/31/2023	398	71	-136	144	N/A
9/30/2023	348	62	-114	128	N/A
6/30/2023	303	116	-48	124	N/A
3/31/2023	256	99	-53	120	N/A
12/31/2022	214	83	106	116	N/A
9/30/2022	192	67	85	95	N/A
6/30/2022	170	54	75	76	N/A
3/31/2022	154	45	65	65	N/A
12/31/2021	141	39	59	60	N/A
9/30/2021	134	42	53	54	N/A
6/30/2021	127	75	43	44	N/A
3/31/2021	120	72	41	42	N/A
12/31/2020	119	75	45	45	N/A
9/30/2020	118	71	44	44	N/A
6/30/2020	120	42	49	49	N/A
3/31/2020	119	43	50	50	N/A
12/31/2019	102	32	35	35	N/A
9/30/2019	73	9	14	14	N/A
6/30/2019	42	-12	N/A	-9	N/A
3/31/2019	13	-29	N/A	-28	N/A
12/31/2018	1	-34	N/A	-26	N/A
9/30/2018	N/A	-25	N/A	-22	N/A
6/30/2018	N/A	-21	N/A	-18	N/A
3/31/2018	N/A	-19	N/A	-16	N/A
12/31/2017	N/A	-18	N/A	-14	N/A
9/30/2017	N/A	-17	N/A	-14	N/A
6/30/2017	N/A	-17	N/A	-15	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-18	N/A	-18	N/A
9/30/2016	N/A	-20	N/A	-18	N/A
6/30/2016	N/A	-20	N/A	-20	N/A
3/31/2016	N/A	-20	N/A	-20	N/A
12/31/2015	N/A	-20	N/A	-18	N/A
9/30/2015	N/A	-18	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-16	N/A
3/31/2015	N/A	-17	N/A	-14	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CPRX 'nin tahmini kazanç büyümesi (yıllık 7.4% ) tasarruf oranının ( 3.3% ) üzerindedir.

Kazançlar ve Piyasa: CPRX şirketinin kazançlarının (yıllık 7.4% ) US pazarından (yıllık 16.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CPRX şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: CPRX şirketinin gelirinin (yıllık 8.4% ) US pazarından (yıllık 10.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CPRX şirketinin gelirinin (yıllık 8.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CPRX 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 23.6 %)

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/12/24 13:08
Gün Sonu Hisse Fiyatı	2025/12/24 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Catalyst Pharmaceuticals, Inc. 16 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Luke Herrmann	Baird
Joel Beatty	Baird
null null	Baird

Catalyst Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2025

Catalyst Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2025

Catalyst Pharmaceuticals, Inc. Reaffirms Full-Year 2025 Revenue Outlook

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2025

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Consensus EPS estimates increase by 16%

Recent updates

Lead Independent Director exercised options and sold US$351k worth of stock

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Insider recently sold US$908k worth of stock

Insider notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2025

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announces an Equity Buyback for $200 million worth of its shares.

Does Catalyst Pharmaceuticals (NASDAQ:CPRX) Deserve A Spot On Your Watchlist?

Executive VP notifies of intention to sell stock

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2025

High number of new directors

Catalyst Pharmaceuticals, Inc. Announces National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology

Catalyst Pharmaceuticals, Inc. Appoints Daniel Curran to the Board of Directors

Catalyst Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2000 Dynamic Index

Co-Founder & Non-Executive Chairman recently sold US$5.2m worth of stock

Co-Founder & Non-Executive Chairman notifies of intention to sell stock

President recently sold US$1.7m worth of stock

Catalyst Pharmaceuticals, Inc. Announces Executive Changes

President notifies of intention to sell stock

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings Are Not Doing Enough For Some Investors

Chief Medical & Regulatory Officer notifies of intention to sell stock

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Reaffirms Full-Year 2025 Revenue Outlook

Catalyst Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 20, 2025

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer recently sold US$696k worth of stock

Insider notifies of intention to sell stock

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2025

Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely

Catalyst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025

Charles B. O’Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc

Catalyst Pharmaceuticals, Inc. Announces Sub- Licensee DyDo Pharma Launches Firapse®? in Japan

Catalyst Pharmaceuticals and SERB S.A. Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease

Executive VP notifies of intention to sell stock

Co-Founder & Chairman notifies of intention to sell stock

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)